biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by SayitLykitizon Feb 15, 2011 7:58pm

265 Views

Post# 18140073

RE: Any News?

Hey MIG,
Have not spoken to BiOasis IR myself... but this is from TechnicalBuy, dated Feb.8th (he covers BTI in a newsletter, as well as his website): The key update is that the company was delayed by several months on the development of its Cognitest, Alzheimer’s disease blood test. The delay had nothing to do with the core of the technology, but rather with an ingredient that was auxililiary to the test process. I am told that all development kinks have been ironed out and that we can expect a steady stream of news over the coming months.

s.

Bullboard Posts

Cybin launches new program phase to treat Major Depressive Disorder